The radiopharma landscape takes shape in neuroendocrine tumors
Itm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map
Novartis’ Lutathera made gut and pancreatic neuroendocrine tumors a bright spot for radiopharma, and at least five clinical-stage competitors are advancing behind it. Readouts over the last seven months range from early-stage updates on novel isotope approaches to top-line looks at late-stage data from competitors planning discussions with FDA.
Last month brought updates on both ends of that spectrum. One was the Jan. 28 announcement from Itm Isotope Technologies Munich SE that its Phase III candidate met its primary endpoint, suggesting it could compete with Novartis AG (SIX:NOVN; NYSE:NVS) in the near term. The other was the Jan. 24 signal from Perspective Therapeutics Inc. (NYSE-A:CATX) that its lead-212 take on the approach is adding responders over time, and has room to dose higher...